Integrins and adhesion molecules as targets to treat inflammatory bowel disease

Curr Opin Pharmacol. 2015 Dec;25:67-71. doi: 10.1016/j.coph.2015.11.007.


Inflammatory bowel diseases (IBD) present a typically relapsing-remitting behavior and are characterized by a disabling and progressive course. Anti-tumor necrosis factor (TNF)-α agents have drastically changed the therapeutic management of IBD. However, a significant proportion of patients does not have a primary response, some patients lose response overtime and/or experience side effects. Recently, anti-adhesion molecules were investigated and showed efficacy with a good safety profile. Vedolizumab was recently approved for both Crohn's disease (CD) and ulcerative colitis (UC) and several other molecules are under evaluation in this field. Anti-adhesion molecules could represent a potential therapeutic option for future therapy in IBD. In this review we report the efficacy and safety of major anti-adhesion drugs in active IBD patients.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Cell Adhesion Molecules / antagonists & inhibitors*
  • Humans
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / metabolism*
  • Integrins / antagonists & inhibitors*
  • Models, Biological
  • Molecular Targeted Therapy / methods*


  • Antibodies, Monoclonal, Humanized
  • Cell Adhesion Molecules
  • Integrins